SVRA - NASDAQ
Savara Inc.
$5.25
+1.9%Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
At a Glance
Live SnapshotSavara Inc. Profit Bridge
Profitability Analysis
Savara Inc. Income Statement
SVRA • NASDAQ
| Savara Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 257K | 0.0 | 0.0 | 0.0 | 400K | 54.0 | 1.5K | 0.0 | 0.0 | 0.0 | 489K | 300K | 500K | 500K | 0.0 | |
GROSS PROFIT | ||||||||||||||||||||
(245K) | (78M) | (44.3M) | (27.9M) | (29M) | (35M) | (1M) | (526K) | (363K) | (0.0) | (146K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-245K | -78M | -44.3M | -27.9M | -29M | -34.8M | -1M | -526K | -363K | 400K | -145.9K | 1.5K | 0.0 | 0.0 | 0.0 | 489K | 300K | 500K | 500K | 0.0 | |
OPERATING INCOME | ||||||||||||||||||||
(123.3M) | (25.2M) | (15.7M) | (11M) | (12.5M) | (14.5M) | (52.2M) | (48.4M) | (30M) | (11.3M) | (39.4M) | (29M) | (21.5M) | (15.7M) | (13.4M) | (9M) | (11.6M) | (27.8M) | (24.8M) | (19.4M) | |
(42.1M) | (25M) | (15.7M) | (10.9M) | (12.4M) | (12M) | (13.1M) | (10.7M) | (11.1M) | (2.8M) | (11M) | (9.5M) | (8.5M) | (7.5M) | (7.2M) | (5.3M) | (5M) | (9.7M) | (8.7M) | (7.2M) | |
(81.4M) | (78M) | (44.3M) | (27.9M) | (29M) | (35M) | (38.8M) | (37.2M) | (18.5M) | (8.2M) | (28.3M) | (19.4M) | (12.9M) | (8.1M) | (5.8M) | (3.7M) | (6.5M) | (17.9M) | (15.9M) | (12M) | |
-123.5M | -103.2M | -60M | -38.8M | -41.5M | -49.3M | -79M | -70M | -30M | -10.9M | -39.4M | -29.3M | -21.5M | -15.6M | -13.4M | -8.5M | -11.3M | -27.3M | -24.3M | -29.8M | |
PRE-TAX INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (88K) | (2.3M) | (1.5M) | (70K) | (11K) | (1.2M) | (468K) | (603K) | (0.0) | (0.0) | (0.0) | (11K) | (1.6K) | (0.0) | (0.0) | (0.0) | (0.0) | |
4.2M | 6.5M | 4.4M | -87.9K | -2.3M | -1.5M | -70K | 0.0 | 0.0 | -452K | -473K | 0.0 | 0.0 | 0.0 | 65.6K | 91.2K | 7.2K | 550K | 2.2M | 0.0 | |
(87K) | -77.9M | -44.2M | -27.8M | -28.9M | -32.5M | (311K) | (526K) | (363K) | -43K | (4K) | (0.0) | -1.4K | -5K | (37.6K) | (19.8K) | (79.7K) | (168K) | (197.8K) | (176.7K) | |
4.7M | 7.3M | 5.3M | 689K | -1.5M | -315K | 852K | 18K | -3.5M | -332K | -469K | 577K | 58.9K | 68.5K | -273.9K | 88.8K | -39.4K | 662.3K | 2.2M | 504.7K | |
-118.8M | -95.9M | -54.7M | -38.2M | -43M | -49.6M | -78.2M | -70M | -33.4M | -11.3M | -39.8M | -28.7M | -21.5M | -15.6M | -13.3M | -8.5M | -11.3M | -26.6M | -22.1M | 29.3M | |
NET INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -8.5M | -3.6M | -357K | (0.0) | (0.0) | -1.4K | -5K | -65.6K | (0.0) | (39.4K) | (0.0) | (0.0) | (9.9M) | |
-118.8M | -95.9M | -54.7M | -38.2M | -43M | -49.6M | -78.2M | -61.5M | -29.8M | -10.9M | -39.8M | -28.7M | -21.5M | -15.6M | -13.3M | -8.5M | -11.3M | -26.6M | -22.1M | -29.3M |
SEC Filings
SVRA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | January 27, 2026 | January 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 09, 2026 | January 09, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 30, 2025 | October 29, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 29, 2025 | October 29, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 02, 2025 | September 02, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 13, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | June 06, 2025 | June 05, 2025 | 2025 | |
8-K 8-K 2025 N/A | May 27, 2025 | May 27, 2025 | 2025 | |
10-Q 10-Q 2025 Q1 Q1 | May 13, 2025 | March 31, 2025 | 2025 |
Related Guides
Continue your SVRA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.